Evidence map›Paper›PMID 25435371›Full record

ReviewOncogene2015

Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

P Mapelli, E O Aboagye, J Stebbing, R Sharma

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

P MapelliDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
E O AboagyeDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
J StebbingDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
R SharmaDepartment of Experimental Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
Hammersmith Hospital · GBImperial College London · GB

Funding

Cancer Research UK 10337Cancer Research UK 12011Cancer Research UK 14549Cancer Research UK 16584Department of Health EME/13/122/01Department of Health NIHR/CS/009/009Department of Health NIHR-RP-011-053Medical Research Council G0700915Medical Research Council MR/J007986/1
6 · The paper itself

Abstract

An understanding of epigenetic drivers of tumorigenesis has developed rapidly during the last years. The identification of these changes including DNA methylation and histone modifications in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a step forward in trying to define underlying biologic processes in this heterogeneous disease. The reversible nature of these changes represents a potential therapeutic target. We present an overview of the current knowledge of epigenetic alterations related to GEP-NETs, focusing on the influence and impact these changes have on pathogenesis and prognosis. The potential role of demethylating agents in the management of this patient population is discussed.

Indexed as

Epigenesis, GeneticChromatin Assembly and DisassemblyCpG IslandsDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationGastrointestinal NeoplasmsGenes, p16Histone Deacetylase InhibitorsHumansMicroRNAsNeuroendocrine TumorsPancreatic NeoplasmsPromoter Regions, GeneticTumor Suppressor ProteinsDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesHistone Deacetylase InhibitorsMicroRNAsRASSF1 protein, humanTumor Suppressor Proteins

Identifiers

PMID25435371
OpenAlexW1972443124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.